EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Investigation of Anti‐Apoptotic Effects and Mechanisms of Astragaloside IV in a Rat Model of Cerebral Ischemia–Reperfusion Injury

Li Yu iD, Weifeng Jin, Defang Deng, Yiru Wang, Qianqian Chen, Yangyang Zhang, Haitong Wan, Yunxiang Chen, Ying Chen, Yu He, Lijiang Zhang

CNS Neuroscience & Therapeutics · 2025

DOI: 10.1111/cns.70209 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2025. Verfasst von Li Yu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Qingshan Lake Science and Technology Innovation Center, Hangzhou Medical College, Hangzhou, China. Hauptthemen laut MEDLINE: Saponins, Reperfusion Injury, Triterpenes, Rats, Sprague-Dawley. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Zhejiang Province, Key R&D Program of Zhejiang.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ischemic stroke is a prevalent and life‐threatening cerebrovascular disease that is challenging to treat and associated with a poor prognosis. Astragaloside IV (AS‐IV), a primary bioactive component of Astragali radix , has demonstrated neuroprotective benefits in previous studies. This study aimed to explore the mechanisms through which AS‐IV may treat cerebral ischemia–reperfusion injury (CIRI).

Methods

Network pharmacology was employed to identify key targets and pathways of AS‐IV in CIRI therapy, combined with molecular docking to predict binding affinity. Male Sprague–Dawley rats were randomly assigned to sham, MCAO/R, AS‐IV, SP600125 (JNK inhibitor), AS‐IV + SP600125, and 3‐n‐Butylphthalide (NBP) groups. Neurobehavioral deficits were assessed, and brain tissue damage was visualized through 2,3,5‐triphenyltetrazolium chloride, H&E, and TUNEL staining. Immunohistochemistry was employed to detect CytC‐ and caspase‐3‐positive cells, while Western blotting, qPCR, and ELISAs were used to analyze apoptosis‐related markers.

Results

A total of 48 key targets of AS‐IV predicted to be involved in the treatment of CIRI were identified, enriched in 136 pathways. AS‐IV was effectively bound to the top five targets from 48 targets, and those associated with the c‐Jun N‐terminal kinase (JNK)/Bid pathway, with binding energy values below −5.0 kJ·mol −1 . JNK inhibition reduced infarcted brain areas, improved neurological function, reduced pathological brain tissue damage, and inhibited apoptosis, with AS‐IV achieving similar neuroprotective effects. Both AS‐IV and SP600125 reduced p‐JNK, Bid, CytC, Apaf‐1, caspase‐3, and cleaved caspase‐3 levels in rats while decreasing CytC, caspase‐3, and caspase‐9 levels in serum.

Conclusion

AS‐IV may suppress apoptosis partly through the modulation of JNK/Bid signaling, exerting neuroprotective effects. These findings support the potential development of AS‐IV‐based therapies for stroke treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SaponinsReperfusion InjuryTriterpenesRats, Sprague-DawleyApoptosisNeuroprotective AgentsMolecular Docking SimulationAnimalsMaleRatsDisease Models, AnimalInfarction, Middle Cerebral ArteryBrain IschemiaNetwork PharmacologyAnthracenes

Stichwörter der Autor:innen

ApoptosisAstragaloside IVCerebral ischemia–reperfusion injuryJNK/BidSP600125

Substanzen

astragaloside ASaponinsTriterpenesNeuroprotective AgentspyrazolanthroneAnthracenes

Autor:innen und Institutionen

  • Qingshan Lake Science and Technology Innovation Center, Hangzhou Medical College, Hangzhou, China.
  • School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
  • Key Laboratory of Drug Safety Evaluation and Research of Zhejiang Province, Center of Safety Evaluation and Research, Hangzhou Medical College, Hangzhou, China.
  • School of Pharmacy, Zhejiang Chinese Medical University, Hangzhou, China.
  • Faculty of Chinese Medicine, Macau University of Science and Technology, Macao, China.

ORCID-Profile: Li Yu

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Zhejiang Province
  • Key R&D Program of Zhejiang
  • Postdoctoral research projects merit-based funding in Zhejiang province (First-class funding)
  • China Postdoctoral Science Foundation

Zitieren

APA

Yu, L., Jin, W., Deng, D., Wang, Y., Chen, Q., Zhang, Y., Wan, H., Chen, Y., Chen, Y., He, Y., & Zhang, L. (2025). Investigation of Anti‐Apoptotic Effects and Mechanisms of Astragaloside IV in a Rat Model of Cerebral Ischemia–Reperfusion Injury. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.70209

Vancouver

Yu L, Jin W, Deng D, Wang Y, Chen Q, Zhang Y, et al. Investigation of Anti‐Apoptotic Effects and Mechanisms of Astragaloside IV in a Rat Model of Cerebral Ischemia–Reperfusion Injury. CNS Neuroscience & Therapeutics. 2025. doi:10.1111/cns.70209

BibTeX
@article{Yu2025,
  author = {Yu, Li and Jin, Weifeng and Deng, Defang and Wang, Yiru and Chen, Qianqian and Zhang, Yangyang and Wan, Haitong and Chen, Yunxiang and Chen, Ying and He, Yu and Zhang, Lijiang},
  title = {Investigation of Anti‐Apoptotic Effects and Mechanisms of Astragaloside IV in a Rat Model of Cerebral Ischemia–Reperfusion Injury},
  journal = {CNS Neuroscience & Therapeutics},
  year = {2025},
  doi = {10.1111/cns.70209}
}
Kostenlos starten →